Vanguard Portfolio Management LLC has filed an amendment to its Schedule 13G, revealing that it beneficially owns 1.33% of Rocket Pharmaceuticals, Inc. This filing is significant as it reflects Vanguard's growing influence in the pharmaceutical sector.

Rocket Pharmaceuticals, which specializes in pharmaceutical preparations, is based in New York and has been making strides in the biotech field. The recent filing was made on October 30, 2026, and it indicates that Vanguard holds 1,463,677 shares of Rocket Pharmaceuticals, with sole voting power over 37,351 shares.

According to the filing, Vanguard Portfolio Management LLC exercises dispositive power over the shares, which includes securities held by Vanguard funds. The filing also notes that no other person's interest in the securities reported exceeds 5%.

This development may affect various stakeholders, including shareholders and management at Rocket Pharmaceuticals, as institutional investors like Vanguard can influence company decisions and strategic direction. The filing emphasizes the vital role that investment firms play in the pharmaceutical industry.

Details were not available in the SEC filing regarding what happens next for Vanguard or Rocket Pharmaceuticals following this disclosure.

The filing also indicates that Vanguard Portfolio Management LLC is classified as an investment advisor (IA) under the SEC regulations. This classification allows Vanguard to manage investments on behalf of its clients, which include various investment companies and managed accounts.

Vanguard's beneficial ownership of Rocket Pharmaceuticals represents 1.33% of the company's common stock, which is a notable stake considering the competitive landscape of the pharmaceutical industry. The filing specifies that Vanguard has sole dispositive power over all 1,463,677 shares, meaning it has the authority to make decisions regarding the sale or transfer of these shares.

Additionally, the SEC filing mentions that Vanguard's ownership does not include securities beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, which could indicate that the total influence of Vanguard in Rocket Pharmaceuticals may be larger than reported.

It is also worth noting that the filing confirms that Vanguard's acquisition of these shares was made in the ordinary course of business and not for the purpose of influencing control over Rocket Pharmaceuticals, which aligns with regulatory requirements.

Despite the detailed information regarding ownership and voting power, the filing does not provide insights into Vanguard's future intentions regarding its investment in Rocket Pharmaceuticals or any specific strategies that may be pursued in light of this ownership stake.